Solt DB
@living.tech
Solt DB is a biotech equities research firm & public benefit company.
Memberships to investment research keep the finch 100% independent and fund our mission to build high-quality, open-source databases for the bioeconomy.
https://www.living.tech/
Memberships to investment research keep the finch 100% independent and fund our mission to build high-quality, open-source databases for the bioeconomy.
https://www.living.tech/
Fiscal 2025 guidance vs. our pre-report model:
➡️ Revenue = $372m vs. $400.733m
➡️ Gross margin = 48% vs. 46.3%
Our 2025 model will be refined with an upgraded gross margin expectation. Revenue will remain unchanged, but higher margins will greatly improve operating loss and cash flow. 👀
$TWST
➡️ Revenue = $372m vs. $400.733m
➡️ Gross margin = 48% vs. 46.3%
Our 2025 model will be refined with an upgraded gross margin expectation. Revenue will remain unchanged, but higher margins will greatly improve operating loss and cash flow. 👀
$TWST
November 18, 2024 at 6:03 PM
Fiscal 2025 guidance vs. our pre-report model:
➡️ Revenue = $372m vs. $400.733m
➡️ Gross margin = 48% vs. 46.3%
Our 2025 model will be refined with an upgraded gross margin expectation. Revenue will remain unchanged, but higher margins will greatly improve operating loss and cash flow. 👀
$TWST
➡️ Revenue = $372m vs. $400.733m
➡️ Gross margin = 48% vs. 46.3%
Our 2025 model will be refined with an upgraded gross margin expectation. Revenue will remain unchanged, but higher margins will greatly improve operating loss and cash flow. 👀
$TWST
Q4 2024 results vs. our model, guidance, and Wall Street:
➡️ Revenue = $84.7m, gross margin = 45.1%, operating loss = $36.044m
➡️ Our model = $86.0m (off by 1.5%), gross margin = 44.2%, operating loss = $39.964m
➡️ Guidance = $82.5m (off by 2.6%), Wall Street models = $81.9m (off by 3.3%)
$TWST
➡️ Revenue = $84.7m, gross margin = 45.1%, operating loss = $36.044m
➡️ Our model = $86.0m (off by 1.5%), gross margin = 44.2%, operating loss = $39.964m
➡️ Guidance = $82.5m (off by 2.6%), Wall Street models = $81.9m (off by 3.3%)
$TWST
November 18, 2024 at 6:03 PM
Q4 2024 results vs. our model, guidance, and Wall Street:
➡️ Revenue = $84.7m, gross margin = 45.1%, operating loss = $36.044m
➡️ Our model = $86.0m (off by 1.5%), gross margin = 44.2%, operating loss = $39.964m
➡️ Guidance = $82.5m (off by 2.6%), Wall Street models = $81.9m (off by 3.3%)
$TWST
➡️ Revenue = $84.7m, gross margin = 45.1%, operating loss = $36.044m
➡️ Our model = $86.0m (off by 1.5%), gross margin = 44.2%, operating loss = $39.964m
➡️ Guidance = $82.5m (off by 2.6%), Wall Street models = $81.9m (off by 3.3%)
$TWST
7/ Many more insights in the article. This scatter plot near the end is interactive (as are all graphics).
It captures every blockbuster in 2023 ranked by Total Sales, U.S. Sales, and Rest of World Sales.
Blockbusters with >$5B in revenue from:
➡️ U.S. = 15
➡️ Ex-U.S. = 3
It captures every blockbuster in 2023 ranked by Total Sales, U.S. Sales, and Rest of World Sales.
Blockbusters with >$5B in revenue from:
➡️ U.S. = 15
➡️ Ex-U.S. = 3
March 26, 2024 at 3:04 PM
7/ Many more insights in the article. This scatter plot near the end is interactive (as are all graphics).
It captures every blockbuster in 2023 ranked by Total Sales, U.S. Sales, and Rest of World Sales.
Blockbusters with >$5B in revenue from:
➡️ U.S. = 15
➡️ Ex-U.S. = 3
It captures every blockbuster in 2023 ranked by Total Sales, U.S. Sales, and Rest of World Sales.
Blockbusters with >$5B in revenue from:
➡️ U.S. = 15
➡️ Ex-U.S. = 3
6/ We also took a deeper dive into the top 3 blockbusters in 2023: Keytruda from Merck $MRK , Humira from AbbVie $ABBV , and Ozempic from Novo Nordisk $NVO .
Ozempic was used off-label for obesity, but it notched a record for 6th year sales of any drug product in history.
Ozempic was used off-label for obesity, but it notched a record for 6th year sales of any drug product in history.
March 26, 2024 at 3:03 PM
6/ We also took a deeper dive into the top 3 blockbusters in 2023: Keytruda from Merck $MRK , Humira from AbbVie $ABBV , and Ozempic from Novo Nordisk $NVO .
Ozempic was used off-label for obesity, but it notched a record for 6th year sales of any drug product in history.
Ozempic was used off-label for obesity, but it notched a record for 6th year sales of any drug product in history.
5/ Blockbuster drugs were equally likely to be a biologic or small molecule in 2023.
However, the top 20 (70%), top 50 (56%), and autoimmune therapies (82%) were more likely to be biologics.
Oncology (43%) and cardiometabolic (35%) drugs less likely to be biologics.
However, the top 20 (70%), top 50 (56%), and autoimmune therapies (82%) were more likely to be biologics.
Oncology (43%) and cardiometabolic (35%) drugs less likely to be biologics.
March 26, 2024 at 3:03 PM
5/ Blockbuster drugs were equally likely to be a biologic or small molecule in 2023.
However, the top 20 (70%), top 50 (56%), and autoimmune therapies (82%) were more likely to be biologics.
Oncology (43%) and cardiometabolic (35%) drugs less likely to be biologics.
However, the top 20 (70%), top 50 (56%), and autoimmune therapies (82%) were more likely to be biologics.
Oncology (43%) and cardiometabolic (35%) drugs less likely to be biologics.
4/ Blockbusters treated 15 therapeutic areas in 2023.
Oncology (26%), cardiometabolic (15%), and autoimmune (11%) had the most -- over half of all blockbusters.
There was also one blockbuster drug for dogs. #barkbark
Oncology (26%), cardiometabolic (15%), and autoimmune (11%) had the most -- over half of all blockbusters.
There was also one blockbuster drug for dogs. #barkbark
March 26, 2024 at 3:02 PM
4/ Blockbusters treated 15 therapeutic areas in 2023.
Oncology (26%), cardiometabolic (15%), and autoimmune (11%) had the most -- over half of all blockbusters.
There was also one blockbuster drug for dogs. #barkbark
Oncology (26%), cardiometabolic (15%), and autoimmune (11%) had the most -- over half of all blockbusters.
There was also one blockbuster drug for dogs. #barkbark
3/ Only 29 drug developers wielded a blockbuster drug in 2023. It's not an easy milestone for smaller or newly commercial companies to achieve.
That count includes Adcetris from SeaGen, which was acquired by Pfizer $PFE later in the year.
That count includes Adcetris from SeaGen, which was acquired by Pfizer $PFE later in the year.
March 26, 2024 at 3:01 PM
3/ Only 29 drug developers wielded a blockbuster drug in 2023. It's not an easy milestone for smaller or newly commercial companies to achieve.
That count includes Adcetris from SeaGen, which was acquired by Pfizer $PFE later in the year.
That count includes Adcetris from SeaGen, which was acquired by Pfizer $PFE later in the year.
2/ Eight (8) blockbusters had sales >$10 billion in 2023.
For perspective, 5 years ago only one crossed this level (Humira) – and only 4 had reached this milestone in history as of 2018 (+Lipitor, Sovaldi, and Harvoni).
This table is searchable and sortable in the article.
For perspective, 5 years ago only one crossed this level (Humira) – and only 4 had reached this milestone in history as of 2018 (+Lipitor, Sovaldi, and Harvoni).
This table is searchable and sortable in the article.
March 26, 2024 at 3:01 PM
2/ Eight (8) blockbusters had sales >$10 billion in 2023.
For perspective, 5 years ago only one crossed this level (Humira) – and only 4 had reached this milestone in history as of 2018 (+Lipitor, Sovaldi, and Harvoni).
This table is searchable and sortable in the article.
For perspective, 5 years ago only one crossed this level (Humira) – and only 4 had reached this milestone in history as of 2018 (+Lipitor, Sovaldi, and Harvoni).
This table is searchable and sortable in the article.
1/ The world's blockbuster drugs generated $507 billion in global sales in 2023, including over $296 billion in the U.S. alone.
The top 25 drugs by U.S. revenue (not overall) overwhelmingly benefitted from a lack of drug pricing regulations in the United States.
The top 25 drugs by U.S. revenue (not overall) overwhelmingly benefitted from a lack of drug pricing regulations in the United States.
March 26, 2024 at 3:00 PM
1/ The world's blockbuster drugs generated $507 billion in global sales in 2023, including over $296 billion in the U.S. alone.
The top 25 drugs by U.S. revenue (not overall) overwhelmingly benefitted from a lack of drug pricing regulations in the United States.
The top 25 drugs by U.S. revenue (not overall) overwhelmingly benefitted from a lack of drug pricing regulations in the United States.